Cardio Catch-Up: Advisory Panel Gives Recor Momentum Toward US Launch Of RDN System

The majority of FDA’s circulatory systems devices panel agreed that ReCor’s Paradise ultrasound renal denervation system offers a safe and effective therapy for patients with hypertension. The panel’s endorsement means ReCor will likely be the first company to reach the US market with an RDN system.

MT2007_FDA Advisory Comm_292512269_1200.jpg
• Source: Shutterstock

More from Clinical Trials

More from R&D